Global Medical Advisory Board

Education

Universidad Nat’l of Columbia, MD Degree in Medicine, 1970.

St. Luke’s Hospital, Cleveland, OH, Resident Internal Medicine, 1971-74

U.T. MD Anderson Hospital, Houston, TX, Fellow Medical Oncology, 1976

A. Positions and Honors Positions and Employment

1976-1977 Faculty Associate, Medical Breast Service, UTMDACC

1977-1980 Assistant Professor of Medicine, UTMDACC

1980-1985 Associate Professor of Medicine, UTMDACC

1980-1985 Director, Fellowship Program, Dept. Medical Oncology, UTMDACC

1984-1992 Chief, Breast Medical Oncology Service, UTMDACC

1985-Present Professor of Medicine, UTMDACC

1992-Present Chairman, Breast Medical Oncology, UTMDACC

1992-Present Director, Breast Cancer Research Program, UTMDACC

1998-Present Nellie B. Connally Chair in Breast Cancer, UTMDACC

Other Experience and Professional Memberships

1975 Diplomat, American Board of Internal Medicine

1977 Diplomat, American Board of Internal Medicine (Medical Oncology)

1993 - Present Corresponding Member - National Academy of Medicine, Argentina

1994 - Present Corresponding Member - National Academy of Medicine, Mexico

1995 Cino del Duca Award (Paris-France)

1997 Brinker International Award (Susan G. Komen Breast Cancer Foundation)

1999 Vermeille Medal of the City of Paris, France

2001 Chevalier de la Legion d’Honneur, Paris, France

2003 Horizon Scientific Achievement Award in Breast Cancer

2003 Glenn Robbins Award, New York Cancer Society

2004 Jeffrey A. Gottlieb Memorial Award

2004 - Present External Member - National Academy of Sciences, Hungary

2005 Laurea Honoris Causa – University of Modena and Reggio Emilia, Italy

2006 Pathfinder Award – American Society of Breast Disease

2006 - 2007 President, American Society of Clinical Oncology

2007 – Present Chair, Southwest Oncology Group Breast Committee

B. Selected peer-reviewed publications (in chronological order).

(Publications selected from over 500 peer-reviewed publications)

Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, and Champlin RE: Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma. J Natl Cancer Inst 92(3):225-233, 2000.

Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Warner DL, Payne JY, Tucker SD, Bartolomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC: Cationic Liposome-Mediated Adenovirus Type 5 E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biological Effects: A Phase I Clinical Trial. J Clin Oncol 19:3422-3433, 2001.

Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer HM, Buchholz TA, and Hortobagyi GN: Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. J Clin Oncol 23(1):41-48, 2004.

Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN: Significantly Higher Pathological Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. J Clin Oncol 23(16):3676-3685, 2005

Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M: Biologic Markers in Axillary Node-Negative Breast Cancer: Differential Expression in Invasive Ductal Carcinoma versus Invasive Lobular Carcinoma. Clin Breast Cancer 7(5):396-400, 2006.

Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, and Hortobagyi GN: Neoadjuvant Therapy with Paclitaxel Followed by 5-Fuorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clin Cancer Res 13(1):228-233, 2007.

Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M: Kinetics of Serum HER-2/neu Changes in Patients with HER-2-Positive Primary Breast Cancer After Initiation of Primary Chemotherapy. Cancer 109(3):496-501, 2007. [Epub ahead of print on December 5, 2006].

Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN: Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients with Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 2007. [Epub ahead of print on July 2, 2007].

Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, Babiera G: Mammography Before Diagnosis Among Women Age 80 and Older with Breast Cancer. J Clin Oncol 2008. [Epub ahead of print on April 21, 2008] PMID: 18427152

Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS: Limits of Observational Data in Determining Outcomes from Cancer Therapy. Cancer 2008. [Epub ahead of print on April 21, 2008] PMID: 18428196

Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF and Hortobagyi GN: The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw in Cancer Patients Treated with Intravenous Bisphosphonates. J Bone Min Res 2008. [Epub ahead of print on February 5, 2008] PMID: 18435574

Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE, Perkins GH, Oh JL, Yu TK, Terrefe W, Sahin AA, Hunt KK, Hortobagyi GN, Buchholz TA: Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer. Int J Radiat Oncol Biol Phys 2008. [Epub ahead of print on April 24, 2008] PMID: 18439768

Srokowski TP, Fang S, Duan Z, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH: Completion of Adjuvant Radiation Therapy Among Women With Breast Cancer. Cancer 2008. [Epub ahead of print on April 28, 2008] PMID: 18442124

Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans FW and Pusztai L: Evaluation of Biological Pathways Involved in Chemotherapy Response in Breast Cancer. Breast Cancer Res 2008. [Epub ahead of print on April 29, 2008] PMID: 18445275

Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW, Meric-Bernstam F, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM; for the Inflammatory Breast Cancer Research Group: Prognostic Significance of HER-2 Status in Women with Inflammatory Breast Cancer. Cancer 112(9):1905-1911, 2008. [Epub ahead of print February 25, 2008]. PMID: 18300243

C. Research Support

1 P50 CA116199-01 Hortobagyi (PI)

9/23/2005 – 8/31/2010

NIH/NCI - UTMDACC SPORE in Breast Cancer

The goal of this project is to foster interactive, multi-specialty translational research in breast cancer diagnosis, prevention and treatment.

Role: PI

2P30 CA016672 28(PP-4) Hortobagyi (PI)

7/1/2003-6/30/2013

DHHS-NIH-NCI

Cancer Center Support (Core) Grant-Project 4-Breast Cancer Program

The major goal of this project is to establish the research infrastructure and organization for the Breast Cancer Research Program at The University of Texas M. D. Anderson Cancer Center.

Role: PI

Susan G. Komen Breast Cancer Foundation

7/1/2002 – 6/30/2010

Interdisciplinary Breast Cancer Fellowship Program

Hortobagyi (Program Director)

The major goal of this grant is to provide interdisciplinary training to physicians specializing in all aspects of the management of breast diseases.

Role: Program Director

ASCO Career Development Award Gonzalez-Angulo (PI)

7/1/2006 - 6/30/2009

The PI3K/PTEN/AKT Signal Transduction Cascade as a Predictor for Response to Therapy and Therapeutic Target in Breast Cancer

Goal: To study the role of the PI3K/PTEN/AKT Signal Transduction Cascade in breast cancer as a classifier, predictor of response, and target for preoperative therapy.

Role: Mentor

NCI: 1 U10 CA105409 Lippman (PI)

U10 Full Member Application Affiliated with SWOG

7/26/04-12/31/09

Goal: Development of Studies

Role: Co-Investigator

NCI: DHHS-NIH: 1 K23 CA12199401 (Gonzalez-Angulo (PI)

The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer

7/1/06-6/30/11

Goal: To study the relationship of P13K, PTEN, and SKT signal transduction in breast cancer.

Role: Consultant

The Breast Cancer Research Foundation: Breast Cancer-Targeted Therapy by Endostatin-Cytosine Deaminase Fusion Protein. (G.N. Hortobagyi, PI)

10/1/2008 – 9/30/2009

Role: PI

Past Support

DHHS–NIH-National Cancer Institute: 3 P50 CA116199-02S1 Bondy (Project PI)

(SPORE Supplement)

9/28/06 – 8/31/2008

Comparative Study of Breast Cancers and their Risk Factors Among Mexican Women in Mexico and the U.S.

Goal: Study the difference of risk factors between Mexican American women in the US and Mexico.

Role: SPORE PI

Entertainment Industry Foundation: EIF/WCRF Breast Cancer Biomarker Discovery Project.

P.I.: Leyland Hartwell

10/5/07 – 10/4/08

Role: Steering Committee Member: October 5, 2007 through October 4, 2008.

NCI: DHHS-NIH (1 K01 CA118174 01) Nahta (PI)

HER-2/IGF-1R Crosstalk and Herceptin Resistance

8/1/06 – 2/15/08

Goal: Study the relationship of HER-2/IGF-1R and Herceptin Resistance.

Role: Investigator

DAMD17-02-1-0694 01 Hortobagyi (PI)

9/1/2002 – 8/31/2007

USAMRMC-DOD Breast Cancer Research Program

Breast Cancer Center of Excellence: Development of Targeted Therapy Strategies for Breast Cancer.

The major goals of this project are to develop an interactive, multidisciplinary center that will combine expertise in molecular biology, novel animal models and clinical trials expertise to expedite the discovery and development of novel targeted therapies.

Role: PI

DAMD17-02-1-0456 1 Pusztai (PI)

4/012002 –4/31/2006

USAMRMC “The Role of Sigma Receptor in Breast Cancer”

The major role of this grant is to study and discover the role of sigma receptors in breast cancer.

Role: Co-Investigator

1RO1CA89608-O1A1 Bondy (PI)

7/1/2000 – 6/30/2006

NCI

Epidemiologic and Genetic Determinants of Breast Cancer Survival

The major goals of this project are to understand the influence of genetic and environmental influences on survival of patients with breast cancer.

Role: Co-Investigator